Dyslipidemia related to antiretroviral therapy

AIDS Reviews

Volumn 13, Issue 1, 2011, Pages 49-56

  Estrada, Vicente ^a   Portilla, Joaquín ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Antiretroviral therapy; Cardiovascular risk; Dyslipidemia; HIV infection

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; CHOLESTEROL; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; PRAVASTATIN; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; ROSUVASTATIN; SIMVASTATIN; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT;

ABSENCE OF SIDE EFFECTS; AGING; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DIABETES MELLITUS; DIET; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; EXERCISE; FATTY ACID METABOLISM; GENETIC ASSOCIATION; GLUCOSE TRANSPORT; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; LIFESTYLE; LIFESTYLE MODIFICATION; LIPID HYDROLYSIS; LIPID LIVER LEVEL; LIPID METABOLISM; NEUROTOXICITY; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SURVIVAL; TREATMENT DURATION; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INHIBITION; CHEMICALLY INDUCED DISORDER; METHODOLOGY; REVIEW;

ANTI-HIV AGENTS; ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS;

EID: 79960635105     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Oh J., Hegele R. HIV-associated dyslipidaemia:Pathogenesis and treatment. Lancet Infect Dis. 2007;7:787-796
2. Riddler S., Li X., Chu H., et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007;8:280-287 (Pubitemid 46901526)
3. Lewden C., May T., Rosenthal E., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005:The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598
4. Riddler S., Li X., Otvos J., et al. Multicenter AIDS Cohort Study. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2008;48:281-288
5. Rizzo M., Berneis K. Lipid triad or atherogenic lipoprotein phenotype:A role in cardiovascular prevention? J Atheroscler Thromb. 2005;12:237-239
6. Lee G., Rao M., Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep. 2005;2:39-50.
7. Hruz P., Murata H., Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy:The search for a central mechanism. Am J Physiol. 2001;280:E549-E553
8. Shahmanesh M., Das S., Stolinski M., et al. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab. 2005;90:755-760 (Pubitemid 40279192)
9. Carpentier A., Patterson B., Uffelman K., Salit I., Lewis G. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis. 2005;178:165-172 (Pubitemid 39600829)
10. Sekhar R., Jahoor F., Pownall H., et al. A. Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriglyceridemia in HIV lipodystrophy syndrome. Am J Clin Nutr. 2005;81:1405-1410 (Pubitemid 41710245)
11. Reeds D., Yarasheski K., Fontana L., et al. Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab. 2006;290:E47-53.
12. van Wijk J, Cabezas M, de Koning E, Rabelink T, van der Geest R, Hoepelman I. In vivo evidence of impaired peripheral fatty acid trapping in patients with HIV-associated lipodystrophy. J Clin Endocrinol Metab. 2005;90:3575-3582
13. Lenhard J., Croom D.K., Weiel J., Winegar D. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000;20:2625-9.
14. Zimmermann R, Panzenböck U, Wintersperger A, et al. Lipoprotein lipase mediates the uptake of glycated LDL in fibroblasts, endothelial cells, and macrophages. Diabetes. 2001;50:1643-1653
15. Carr A., Samaras K., Chisholm D., Cooper D. Pathogenesis of HIV-1- protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883 (Pubitemid 28279721)
16. Gregor M., Hotamisligil G. Adipocyte stress:The endoplasmic reticulum and metabolic disease. J Lipid Res. 2007;48:1905-1914 (Pubitemid 47360610)
17. Parker R., Flint O., Mulvey R., et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol. 2005;67:1909-1919 (Pubitemid 41007773)
18. Liang J., Distler O., Cooper D., et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome:A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327-1331 (Pubitemid 34007937)
19. Petit J.M., Duong M., Duvillard L., et al. LDL-receptors expression in HIVinfected patients:Relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy. Eur J Clin Invest. 2002;32:354-359 (Pubitemid 36228396)
20. Riddle T., Kuhel D., Woollett L., Fichtenbaum C., Hui D. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory elementbinding proteins in the nucleus. J Biol Chem. 2001;276:37514-37519
21. Makishima M., Okamoto A., Repa J., et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362-1365 (Pubitemid 29289663)
22. Mencarelli A., Cipriani S., Renga B., et al. The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. PLoS One. 2010;5:e13238.
23. Rotger M., Bayard C., Taffé P., et al. Swiss HIV Cohort Study. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals:A longitudinal study. Circ Cardiovasc Genet. 2009;2:621-628
24. Hulgan T., Haubrich R., Riddler S., et al. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS. 2011;25:37-47.
25. Fontas E., Van Leth F., Sabin C., et al. D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy:Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074 (Pubitemid 38373099)
26. Crane H., Grunfeld C., Willig J., et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25:185-195
27. Gallant J., Staszewski S., Pozniak A., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients:A 3-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
28. Podzamczer D., Ferrer E., Sanchez P., et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine:96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139-147 (Pubitemid 46292215)
29. Gallant J., De Jesus E., Arribas J.R., et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260 (Pubitemid 43113030)
30. Smith K., Patel P., Fine D., et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23: 1547-1556
31. Sax P., Tierney C., Collier A., et al. Abacavir-lamivudine versus tenofovir- emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361: 2230-2240
32. Post F., Moyle G., Stellbrink H., et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults:48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-57.
33. Martínez E., Arranz J., Podzamczer D., et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixeddose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290-297
34. Martin A., Bloch M., Amin J., et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine:A randomized, 96- week trial. Clin Infect Dis. 2009;49:1591-1601
35. Tungsiripat M., Kitch D., Glesby M., et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy:ACTG 5206. AIDS. 2010;24:1781-1784
36. Worm S., Sabin C., Weber R., et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes:The data collection on adverse events of anti- HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-330
37. Franssen R., Sankatsing R., Hassink E., et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009;29:1336-1341
38. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus dela inmunodeficiencia humana. Updated January 2011. Available at: http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011- Documentoconsenso-TAR-adulto-verordenador.pdf
39. Shikuma C., Yang Y., Glesby M., et al. Metabolic effects of protease inhibitor- sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44:540-550
40. Riddler S., Haubrich R., Di Rienzo A., et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106 (Pubitemid 351679596)
41. Pérez-Molina J., Domingo P., Martínez E., Moreno S. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother. 2008;62:234-245 (Pubitemid 351984766)
42. Milinkovic A., Martínez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther. 2004;2:367-373 (Pubitemid 38745097)
43. Soriano V., Arasteh K., Migrone H., et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral- naive HIV-1 patients: the ARTEN trial. Antivir Ther. [In press].
44. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
45. Schiller D., Youssef-Bessler M. Etravirine:A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTIresistant strains of HIV. Clin Ther. 2009;31:692-704.
46. Madruga J., Cahn P., Grinsztejn B., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38. (Pubitemid 47017466)
47. Lazzarin A., Campbell T., Clotet B., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48. (Pubitemid 47017467)
48. Estrada V., De los Santos I., Sanz J. Evolución de los lípidos plasmáticos tras el cambio a etravirina en pacientes con supresión viral. II Congreso Nacional GESIDA, November 2010, Madrid. [Abstract P016].
49. Waters L., Fisher M., Winston A., et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2011;25:65-71.
50. Hill A., Sawyer W., Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials. 2009;10:1-12.
51. Croxtall J., Perry C. Lopinavir/Ritonavir:A review of its use in the management of HIV-1 infection. Drugs. 2010;70:1885-1915
52. Walmsley S., Bernstein B., King M., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Eng J Med. 2002;346:2039-2046 (Pubitemid 34680595)
53. Eron J., Yeni P., Gathe J., et al. The Klean study:Fosamprenavir- ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for the initial treatment of HIV infection over 48 weeks:A randomized non-inferiority trial. Lancet. 2006;368:476-482 (Pubitemid 44160731)
54. Von Hentig N. Atazanavir/ritonavir:A review of its use in HIV therapy. Drugs Today (Barc). 2008;44:103-132 (Pubitemid 351587980)
55. Molina J., Andrade-Villanueva J., Echevarria J., et al. Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV infected patients:48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-655
56. Molina J., Andrade-Villanueva J., Echevarria J., et al. Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviralnaive HIV-1-infected patients:96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323-332
57. Squires K., Young B., De Jesus E., et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/ lamivudine after initial suppression with abacavir/lamivudine plus ritonavir- boosted atazanavir in HIV-infected patients. AIDS. 2010;24:2019.
58. Gatell J., Salmon-Ceron D., Lazzarin A., et al. Efficacy and safety of atazanavir based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen:The SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44:1484-1492 (Pubitemid 46801594)
59. Clotet B., Bellos N., Molina J., et al. Efficacy and safety of darunavir at week 48 in treatment-experienced patients with HIV infection in POWER 1 and 2:A pooled subgroup analysis of data from two randomized trials. Lancet. 2007;369:1169-1178 (Pubitemid 46541620)
60. Arastéh K., Yeni P., Pozniak A., et al. Efficacy and safety of darunavir/ ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14:859-864
61. Valdez Madruga J., Berger D., McMurchie M., et al. Efficacy and safety of darunavir-ritonavir with that of lopinavir-ritonavir at 48 weeks in treatment- experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58.
62. Ortiz R, De Jesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-infected patients at week 48. AIDS. 2008;22:1389-1397
63. Mills A., Nelson M., Jayaweera D., et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-infected patients:96-week analysis. AIDS. 2009;23:1679-1688
64. Overton T., Aberg J., Gupta S., Ryan R., Baugh R., De La Rosa G. Metabolic: Week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir. 10th International Congress on Drug Therapy in HIV Infection, November 2010. Glasgow, UK. [Abstract P74].
65. Emery S., Winston A. Raltegravir:A new choice in HIV and new chances for research. Lancet. 2009;374:764-766
66. Lennox J., De Jesus E., Lazzarin A., et al. Safety and efficacy of raltegravir- based versus efavirenz combination therapy in treatment-naïve patients with HIV infection:A multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
67. Martínez E., Larrouse M., Llibre J., et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients:The SPIRAL study. AIDS. 2010;24:1697-1707
68. Cooper D., Heera J., Goodrich J., et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral- naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201:803-813
69. Perry C. Maraviroc:A review of its use in the management of CCR5- tropic HIV-1 infection. Drugs. 2010;70:1189-1213
70. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421
71. European AIDS Clinical Society Guidelines. Non infectious co-morbidities. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/ 2-Non-Infectious-Co-Morbidities-in-HIV.pdf
72. Friis-Møller N., Thiébaut R., Reiss P., et al. Predicting the risk of cardiovascular disease in HIV-infected patients:The data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010; 17:491-501.
73. Grundy S., Cleeman J., Merz C., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
74. Alberg J. Lipid Management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin N Am. 2009;38:207-222
75. Calza I., Manfredi R., Colangeli V., et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005:19:1051-1058 (Pubitemid 40961145)
76. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr W, Lundgren J, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296
77. Thompson M., Aberg J., Cahn P., et al. Antiretroviral treatment of adult HIV infection:2010 recommendations of the International AIDS Society- USA panel. JAMA. 2010;304:321-333
78. Calza L., Manfredi R., Colangeli V., et al. Efficacy and safety of atazanavirritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDs. 2009;23:691-697
79. Eron J., Young B., Cooper D., et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2):Two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
80. Ena J., Leach A., Nguyen P. Switching from suppressive protease inhibitor- based regimens to nevirapine-based regimens:A meta-analysis of randomized controlled trials. HIV Med. 2008;9:747-756
81. De Lazzari E., León A., Arnaiz J., et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med. 2008;9:221-226 (Pubitemid 351467795)
82. Ray G. Antiretroviral and statin drug-drug interactions. Cardiol Rev. 2009;17:44.
83. Calza L., Manfredi R., Colangeli V., Pocaterra D., Pavoni M., Chiodo F. Rosuvastatin, pravastatin and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Cur HIV Res. 2008;6:572-578
84. Singh S., Willig J., Mugavero M., et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011; 52:387-395
85. Wohl D., Waters D., Simpson R., et al. Ezetimibe alone reduces lowdensity lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008;47:1105-1108
86. Samineni D., Fichtenbaum C. Fenofibrate in the treatment of dyslipidemia associated with HIV infection. Expert Opin Drug Metab Toxicol. 2010; 6:995-1004.